Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.
To compare a complex induction multimodality protocol (ESPATUE) + concurrent immunotherapy with PD-L1 antibody Durvalumab given every three weeks to the same induction multimodality protocol without Durvalumab immunotherapy induction followed by definitive local treatment (surgery for those considered resectable or chemoradiation boost for those not considered to be R0-resectable) followed by consolidation Durvalumab treatment in both arms.
NSCLC, Stage III
DRUG: Durvalumab
Progression-free survival (PFS), Two-year progression-free survival rate, 2 years
Overall survival, after 1, 2, 3, 4 and 5 years|2-y-overall survival rate, 2 years|Functional response, to investigate functional response (PET-CT-scan) to induction therapy prior to thoracotomy, Week 15|RECIST response (induction), to investigate RECIST response to induction therapy in the whole Population and in both arms., Week 9|RECIST criteria, Radiological response, Through study completion, an average of every 2 months for up to 11 months|EORTC QLQ-C30, Quality of life (QLQ-C30), Through study completion, an average of every 6 weeks for up to 11 months|EORTC QLQ-LC13, Quality of life (QLQ-Lung Cancer 13(LC13)), Through study completion, an average of every 6 weeks for up to 11 months|FACT-L, Quality of life (Functional Assessment of Cancer Therapy-Lung (FACT-L)), Through study completion, an average of every 6 weeks for up to 11 months
To compare a complex induction multimodality protocol (ESPATUE) + concurrent immunotherapy with PD-L1 antibody Durvalumab given every three weeks to the same induction multimodality protocol without Durvalumab immunotherapy induction followed by definitive local treatment (surgery for those considered resectable or chemoradiation boost for those not considered to be R0-resectable) followed by consolidation Durvalumab treatment in both arms.